Previous 10 | Next 10 |
Savara (NASDAQ: SVRA ) : Q2 GAAP EPS of -$0.16 beats by $0.04 . More news on: Savara Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q1 2021 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the ...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. ...
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT. Interested parties can access a live audio webcast on the Inve...
Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the C...
Savara Inc. (SVRA) Q1 2020 Earnings Conference Call May 7, 2020 4:30 p.m. ET Company Participants Anne Erickson - VP, IR and Corporate Communications Rob Neville - CEO Badrul Chowdhury - Chief Medical Officer Dave Lowrance - CFO Taneli Jouhikainen - COO Conference Call Par...
Savara (NASDAQ: SVRA ): Q1 GAAP EPS of -$0.27 beats by $0.01 . More news on: Savara Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a business update. “With the re...
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m...
News, Short Squeeze, Breakout and More Instantly...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...
Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP)...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live web...